In conclusion, SGLT2 inhibitors mitigate serious hyperkalemia risk without elevating the risk of hypokalemia in individuals with type 2 diabetes, high cardiovascular risk, or chronic kidney disease (Neuen et al., 2022). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.